Home / Business and Economy / Big Food's Ozempic Dilemma: Fight or Adapt?
Big Food's Ozempic Dilemma: Fight or Adapt?
1 Dec
Summary
- Food giants struggle to sell processed snacks to Ozempic users.
- McDonald's extends $5 meal deal, targets low-income customers.
- Nestle launches protein-rich meals and supplements for GLP-1 users.
The rise of weight loss drugs like Ozempic has created a significant challenge for the Big Food industry, forcing major corporations to reassess their product offerings. Companies are reportedly meeting to devise strategies in response to consumers actively avoiding high-sugar, processed snacks. This shift presents a pivotal moment for these giants as they navigate a post-semaglutide market reality.
McDonald's, for instance, has seen a sales downturn and is extending its $5 meal promotion, with executives believing Ozempic is affecting purchasing habits. Their strategy appears to focus more on lower-income consumers who may have less access to these medications. This comes after previous attempts to offer healthier options, like salads, failed to gain traction.
Nestle is pursuing a different approach, launching brands like Vital Pursuit with protein-enriched meals and fiber-rich options to address side effects like muscle loss and constipation common among GLP-1 users. They've also entered the supplement market, offering products to combat deficiencies potentially caused by these drugs, signaling a significant industry pivot.
